N.V. GALEEVA

 Kazan State Medical University, Kazan

 Contact details:

Galeeva N.V. — Ph. D. (medicine), Associate Professor of the Department of Infectious Diseases

Address: 49 Butlerov St., Russian Federation, Kazan, 420073, tel.: +7-919-640-16-62, e-mail: Nelli_04@mail.ru

The purpose — to study the level of activity of 5`-nucleotidase in patients with HCV at the stage of the disease natural course exacerbation and its correction by intravenous ozone therapy.

Material and methods. 74 patients with HCV were under observation. The results were analyzed in three groups of patients with HCV, depending on the number of Tr, according to the phases of disseminated intravascular coagulation syndrome: the first group — hypercoagulation phase (Tr > 350 x 109/l, n = 5); the second group — transition phase (PF) between hyper- and hypocoagulation (Tr 350–200 x 109/l, n = 25); the third group — hypocoagulation (Tr < 200 x 109/l, n = 44) which included patients with liver cirrhosis (n = 18) in the outcome of HCV.

Ozone therapy was performed by intravenous infusion with continuous barbating of ozonated saline solution with a course of 5 procedures every other day. The content of the ozone gas mixture during the procedure was calculated depending on the patient’s weight using the formula: m (kg) х 20 mcg/l.

Results. In patients with natural course of HCV during the period of the disease exacerbation, the activity index of 5`-nucleotidase was statistically significantly higher than that of healthy individuals in all the studied groups. A statistically significantly higher level of 5`-nucleotidase was recorded in patients with HCV in the hypocoagulation phase compared to the intermediate phase and the hypercoagulation phase. An inverse correlation between the level of 5`-nucleotidase and the number Tr and a direct correlation with the value of alanine aminotransferase was found. Intravenous ozone therapy with a course of five procedures every other day reduced the enzyme activity.

Key words: 5`-nucleotidase, ozone therapy, chronic hepatitis C.

REFERENCES

1. Shishlo L.M., Prokhorova V.I., Zaytsev L.A. Features of hemostasis in primary liver cancer. Onkologicheskiy zhurnal, 2017, vol. 11, no. 3, pp. 78–85 (in Russ.).
2. Bilalova A.R., Makashova V.V., Astrina O.S., Aleshina N.I. Features of the hemostasis system in patients with chronic hepatitis and liver cirrhosis. Infektsionnye bolezni, 2015, vol. 13, no. 3, pp. 37–45 (in Russ.).
3. Morozov Yu.A., Mednikov R.V., Charnaya M.A. Violations of the hemostatic system in liver pathology and their diagnosis. Gemorragicheskie diatezy, trombozy, trombofilii, 2014, no. 1, pp. 162–174 (in Russ.).
4. Yagoda A.V., Koroy P.V. Patologiya pecheni i funktsiya trombotsitov (kliniko-patogeneticheskiy analiz) [Liver pathology and platelet function (clinical and pathogenetic analysis)]. Stavropol: StGMA, 2008. 273 p.
5. Shklyaev A.E., Malakhova I.G. Predictive value of hemostasis indicators in liver diseases. Tromboz, gemostaz i reologiya, 2016, vol. 67, no. 3, pp. 462–464 (in Russ.).
6. Rupasova A.R., Sorokina A.Yu. Viral hepatitis. Mezhdunarodnyy studencheskiy nauchnyy vestnik, 2018, no. 4, pp. 317–320 (in Russ.).
7. Kurtov I.V., Davydkin I.L., Khaertdinov R.K., Kosyakov Yu.A. et al. Violation of hemostasis in patients with chronic hepatitis and cirrhosis of the liver of viral etiology (HCV), complicated by thrombocytopenia. Vestnik RUDN, seriya Meditsina, 2010, no. 3, pp. 139–141 (in Russ.).
8. Zubairov D.M. Molekulyarnye osnovy svertyvaniya krovi i tromboobrazovaniya [Molecular bases of blood coagulation and thrombus formation]. Kazan: Fen, 2000. 367 p.
9. Santucci R.A, Erlich J., Labriola J. et. Al. Measurement of tissue factor activity in whole blood. Thromb. Haemost, 2000, vol. 83 (3), pp. 445–454.
10. Tozzi M.G., Pesi R., Allegrini S. On the physiological role of cytosolic 5`-nucleotidase II (CN-II): pathological and tyerapeutical implications. Cur Med Chem, 2013, vol. 34 (20), rr. 4285–4291.
11. Chekman I.S., Syrovaya A.O., Makarov V.A. et al. Ozon i ozonirovanie [Ozone and ozonation]. Kharkov: Tsifrovadrukarnya, 2013. No. 1. 144 p.
12. Maslennikov O.V., Kontorshchikova K.N., Shakhov B.E. Rukovodstvo po ozonoterapii [Ozone Therapy Guide]. Nizhniy Novgorod, 2015. 346 p.
13. Viebahn-Hänsler R., Fernández O.S.L., Fahmy Z. Oz one in medicine: the low-dose ozone concept – guidelines and treatment strategies. Ozone Science & Engineering, 2012, vol. 34 (6), rr. 408–424.
14. Peretyagin P.V., Martusovich A.K., Peretyagin S.P. Experimental assessment of the state of microcirculation with systemic administration of ozonized physiological solution. Bioradikaly i antioksidanty, 2015, vol. 54, no. 1, pp. 54-61 (in Russ.).
15. Palonik P.P., Tarpetskiy V.V., Muradyan S.A., Kachura E.V. Possibilities of using ozone in the correction of hemostasis disorders in acute pancreatitis. Studencheskiy vestnik, 2017, vol. 15, no. 6, pp. 15–17 (in Russ.).
16. Maleev V.V., Polyakova A.M., Kravchenko A.V. Narusheniya gemostaza pri infektsionnykh zabolevaniyakh [Violations of hemostasis in infectious diseases]. Moscow: De-Novo, 2005. 160 p.
17. Child C.G. III, Turcotte J.G. Surgery and portal hypertension. In: Child CG III (Hrsg) The liver and portal hypertension. WB Saunders, Philadelphia, 1964, pp. 50–64.
18. Louie K.S., Laurent S.St., Forssen U. et al. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis, 2012, vol. 12 (86), pp. 11–17.
19. Zubairov D.M., Andrushko I.A. Sposob otsenki tromboplastinemii po opredeleniyu aktivnosti markernogo fermenta 5`-nukleotidazy: metodicheskie rekomendatsii [Method for assessing thromboplastinemia by determining the activity of the marker enzyme 5`-nucleotidase: guidelines]. Kazan, 1987. P. 9.
20. Kipenskiy A.V., Glukhen’kaya T.A. Development of a method for correcting ozone dosage in procedures for intravenous infusion of ozonized saline solution. Visnik NTU «KhPI», 2014, no. 36, pp. 161–172 (in Russ.).
21. Kostina O.V., Peretyagin S.P., Struchkov A.A. Determination of the optimal ozone doses based on the assessment of the hemostatic system indicators in burned patients. Klinicheskaya meditsina, 2013, vol. 5, no. 3, pp. 79–82 (in Russ.).
22. Madrid Declaration on ozone therapy: official document of ISCO3 (2nd edition). International Scientific Committee of Ozone Therapy. Madrid: Grafox Imprenta, S.L., 2015. 50 p.
23. Gulyaeva I.L., Pestrenin L.D., Logunov A.V. et al. Pathology of hemostasis and endothelial dysfunction in hepatitis B: current state of the art. Tromboz, gemostaz i reologiya, 2017, vol. 72, no. 4, pp. 14–19 (in Russ.).
24. Shchekotov A.P. Markers of endothelial damage and platelet aggregation in chronic hepatitis and liver cirrhosis. Klinitsist, 2012, vol. 31, no. 1, pp. 31–35 (in Russ.).
25. Starikova M.A., Sidorkin V.G., Sidorkina A.N., Strelkova I.G. Activity of 5′-nucleotidase and alkaline phosphatase in blood in the dynamics of burn disease. Kazanskiy meditsinskiy zhurnal, 2009, vol. 90, no. 5, pp. 691–695 (in Russ.).
26. Nazarov E.I. An adaptive approach to explaining the therapeutic effect of ozone, xenon and hydrogen. Vestnik fizioterapii i kurortologii, 2019, no. 3, pp. 9–33 (in Russ.).
27. Fazylov V.Kh., Galeeva N.V., Zagidullina A.I., Tairov I.N. Ozone therapy in the clinic of infectious diseases. Prakticheskaya meditsina, 2013, vol. 74, no. 5, pp. 48–51 (in Russ.).
28. Galeeva N.V., Fazylov V.Kh., Valeeva I.Kh. Clinical and biochemical substantiation of ozone therapy in chronic viral hepatitis B and C. Kazanskiy meditsinskiy zhurnal, 2014, vol. 95, no. 5, pp. 751–756 (in Russ.).
29. Levitan B.N. Relationship of antiendotoxin antibody concentrations and tumor necrosis factor with pathology of hemostasis and fibrinolysis in chronic hepatitis and liver cirrhosis. Tromboz, gemostaz i reologiya, 2017, vol. 72, no. 4, pp. 70–74 (in Russ.).
30. Veber V.R., Fishman B.B., Kulikov V.E. et al. Variants of associations of clinical and biological indicators and blood cytokines in liver cirrhosis. VICh — infektsiya i immunosupressiya, 2018, vol. 10, no. 1, pp. 47–53 (in Russ.).